Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

NCT00562575 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertriglyceridemia

Interventions

DRUG: SLx-4090
DRUG: Placebo

Sponsor

Response Pharmaceuticals